Macomics is a macrophage drug discovery company, passionate about the therapeutic potential of targeting macrophages for better therapies. We are developing novel treatments for diseases where current therapeutics are severely limited or ineffective.
Our validated and proprietary platform, ENIGMAC™ enables the translation of human disease-specific macrophage biology into genetically validated and actionable therapeutic targets. Our Macrophage Atlas is one of the largest pan-disease and healthy tissue macrophage RNAseq collections globally. Using this vast resource and our bioinformatics expertise, we explore fundamental questions about conserved pathways in healthy and disease states, shedding light on the role of macrophages in driving disease.
We are focused on developing a proprietary pipeline in CRPC, Fibrosis and neurodegeneration
Company Details
- Employees
- 23
- Founded
- -
- Address
- 137a George Street, Edinburgh,scotland Eh2 4jy,united Kingdom
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- macomics.com
- Keywords
- macrophage, oncology, immune system, immuno-oncology, cancer, tumour, therapeutics, drugs, TAM, TME, Fibrosis, neurodegeneration, neuroinflammation.
- HQ
- Edinburgh, Scotland
Macomics Questions
Macomics's website is macomics.com
Macomics's LinkedIn profile is https://uk.linkedin.com/company/macomics
Macomics has
23 employees.
View email and phone details for 23
employees at Macomics.
Macomics's industry is
Biotechnology Research
Macomics's top competitors are
Kynos Therapeutics,
Invizius,
Nanosyrinx,
Bit.bio,
T-Therapeutics Ltd,
Mestag Therapeutics,
Maxion Therapeutics,
Amphista Therapeutics Limited,
Elasmogen Ltd,
Dunad Therapeutics.
Macomics's support email address is info@macomics.com
Macomics's categories are Biotechnology Research
Macomics's founding year is 2020
